Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis

Fig. 3

Summary of pooled results about the HBV DNA undetectable rate in ETV plus Tα1 group and ETV alone group. The duration of treatment in subgroup analyses included both less than or equal to 24 weeks and more than 24 weeks. “Events” represents the number of subjects undetected with HBV DNA. “Total” represents the number of subjects in that group. “Test for overall effect” represents the pooled estimate of risk ratio after comprehensive analysis of all studies. Blue boxes indicate the dichotomous data in the forest plots. CI, confidence interval; M-H, Mantel-Haensel

Back to article page